Maia Biotechnology Doses First Patients in Europe in Ongoing Phase II Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment

The primary objectives of the THIO-101 trial were to evaluate the safety and tolerability, as well as preliminary clinical efficacy of THIO, a first-in-class cancer telomere targeting agent, in patients with advanced NSCLC, who either progressed or relapsed through the initial treatments with an immune checkpoint inhibitor alone, or in combination with chemotherapy.
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News